The 3rd Annual Vision Bowl in Wisconsin was once again a rousing success, topping last year’s mark of $10,000 raised! Once again, attendees sold out the New Berlin Alehouse & Bowling Center for an afternoon of bowling, food friendship and fun!
Part of the event was a huge Silent Auction and Raffle, with bowlers running back and forth from their lanes to the Auction and Raffle room to buy tickets and increase their bids on some amazing items donated by local companies and friends.
London, 11 January 2015 – NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies to patients, has received both U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Orphan Drug Designation for its lead programme, a gene therapy to treat Choroideremia, an X-linked recessive disorder that leads to progressive blindness.
Orphan Drug Designation, which is intended to facilitate drug development for rare diseases, provides substantial benefits to the sponsor, including regulatory support in development activities such as protocol assistance, reduced fees, tax incentives and several years of market exclusivity for the product upon regulatory approval.